S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65

Pfizer Stock Competitors

-0.17 (-0.41 %)
(As of 10/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume21.70 million shs
Average Volume30.08 million shs
Market Capitalization$231.67 billion
P/E Ratio17.73
Dividend Yield3.76%


Should you be buying Pfizer stock or one of its competitors? The main competitors of Pfizer include Johnson & Johnson (JNJ), Eli Lilly and (LLY), Merck & Co., Inc. (MRK), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Horizon Therapeutics Public (HZNP), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), and Perrigo (PRGO). These companies are all part of the "pharmaceuticals" industry.

Pfizer vs.

Pfizer (NYSE:PFE) and Eli Lilly and (NYSE:LLY) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, community ranking, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

Pfizer has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500.

Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 3.8%. Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.4%. Pfizer pays out 70.3% of its earnings in the form of a dividend. Eli Lilly and pays out 42.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Pfizer has a net margin of 23.06% compared to Eli Lilly and's net margin of 22.71%. Eli Lilly and's return on equity of 119.12% beat Pfizer's return on equity.

Company Net Margins Return on Equity Return on Assets
Pfizer 23.06% 26.49% 10.73%
Eli Lilly and 22.71% 119.12% 15.81%

Pfizer has higher revenue and earnings than Eli Lilly and. Pfizer is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$41.91 billion5.53$9.62 billion$2.2218.61
Eli Lilly and$24.54 billion9.34$6.19 billion$7.9330.14

64.9% of Pfizer shares are held by institutional investors. Comparatively, 81.7% of Eli Lilly and shares are held by institutional investors. 0.1% of Pfizer shares are held by company insiders. Comparatively, 0.1% of Eli Lilly and shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Pfizer presently has a consensus price target of $44.00, suggesting a potential upside of 6.49%. Eli Lilly and has a consensus price target of $259.06, suggesting a potential upside of 8.40%. Given Eli Lilly and's stronger consensus rating and higher possible upside, analysts clearly believe Eli Lilly and is more favorable than Pfizer.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
0 Sell rating(s)
9 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
Eli Lilly and
0 Sell rating(s)
1 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)

Pfizer received 362 more outperform votes than Eli Lilly and when rated by MarketBeat users. Likewise, 72.52% of users gave Pfizer an outperform vote while only 71.58% of users gave Eli Lilly and an outperform vote.

PfizerOutperform Votes
Underperform Votes
Eli Lilly andOutperform Votes
Underperform Votes

In the previous week, Pfizer had 39 more articles in the media than Eli Lilly and. MarketBeat recorded 56 mentions for Pfizer and 17 mentions for Eli Lilly and. Pfizer's average media sentiment score of 0.24 beat Eli Lilly and's score of 0.08 indicating that Pfizer is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
12 Very Positive mention(s)
16 Positive mention(s)
17 Neutral mention(s)
2 Negative mention(s)
5 Very Negative mention(s)
Eli Lilly and
2 Very Positive mention(s)
4 Positive mention(s)
7 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)


Eli Lilly and beats Pfizer on 12 of the 21 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PFE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Pfizer (NYSE:PFE) vs. Its Competitors

TypePfizerPharmaceutical IndustryMedical SectorNYSE Exchange
Dividend Yield3.76%2.53%1.96%2.77%
P/E Ratio17.7323.9032.4327.59
Net Margins23.06%-3,378.35%-3,880.25%-85.67%

Pfizer Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Johnson & Johnson
2.7714 of 5 stars
Eli Lilly and
2.8764 of 5 stars
+63.6%$229.19B$24.54B35.832,020Upcoming Earnings
Dividend Announcement
Merck & Co., Inc.
2.9958 of 5 stars
-3.4%$195.30B$47.99B35.2373,500Short Interest ↓
3.54 of 5 stars
Bristol-Myers Squibb
3.3648 of 5 stars
-7.0%$126.53B$42.52B-25.0830,250Analyst Revision
2.3548 of 5 stars
+24.0%$96.08B$6.68B50.8111,300Dividend Announcement
Horizon Therapeutics Public
2.345 of 5 stars
Royalty Pharma
3.0164 of 5 stars
-11.5%$22.48B$2.12B23.1451Dividend Announcement
Short Interest ↑
News Coverage
Jazz Pharmaceuticals
3.0183 of 5 stars
2.7214 of 5 stars
-5.5%$5.99B$5.06B-17.4211,500News Coverage
Nektar Therapeutics
2.2514 of 5 stars
Pacira BioSciences
2.6242 of 5 stars
-5.2%$2.36B$429.65M13.58624Analyst Report
Analyst Revision
News Coverage
Corcept Therapeutics
2.7998 of 5 stars
Supernus Pharmaceuticals
1.9864 of 5 stars
Endo International
2.0898 of 5 stars
-16.5%$971.36M$2.90B14.863,397Analyst Upgrade
2.0848 of 5 stars
BioDelivery Sciences International
2.6583 of 5 stars
+10.6%$402.28M$156.47M12.36176Short Interest ↓
Analyst Revision
News Coverage
1.9209 of 5 stars
-50.8%$354.35M$73.81M-2.48277Gap Down
High Trading Volume
Paratek Pharmaceuticals
2.0648 of 5 stars
Assembly Biosciences
2.0943 of 5 stars
2.1314 of 5 stars
Cumberland Pharmaceuticals
1.5915 of 5 stars
N/A-9.2%$41.07M$37.44M-276,000.0090Short Interest ↓
Gap Up
This page was last updated on 10/19/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.